mitoxantrone hydrochloride liposome + enlonstobart

Mitoxantrone hydrochloride liposome + enlonstobart is a combination therapy being investigated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Mitoxantrone hydrochloride liposome (PLM60) is a liposomal formulation of the synthetic anthracenedione antineoplastic agent mitoxantrone, designed to enhance tumor-specific delivery and reduce systemic toxicities, particularly cardiotoxicity. It acts by intercalating into DNA and inhibiting DNA topoisomerase II, leading to double-strand breaks and apoptosis. Enlonstobart (SG001) is an investigational humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), enlonstobart restores the anti-tumor activity of exhausted T-cells. This combination is currently being evaluated in a Phase Ib/II study sponsored by Sun Yat-Sen University Cancer Center to determine the optimal dose and assess the synergistic efficacy of cytotoxic chemotherapy and immune checkpoint inhibition in PTCL patients.

Brand names

Duoenda

Other names

mitoxantrone hydrochloride liposome and enlonstobartPLM60 and SG001PLM-60 and SG001PLM 60 and SG001